263 related articles for article (PubMed ID: 35711422)
1. Potential Benefits of TNF Targeting Therapy in Blau Syndrome, a NOD2-Associated Systemic Autoinflammatory Granulomatosis.
Matsuda T; Kambe N; Takimoto-Ito R; Ueki Y; Nakamizo S; Saito MK; Takei S; Kanazawa N
Front Immunol; 2022; 13():895765. PubMed ID: 35711422
[TBL] [Abstract][Full Text] [Related]
2. Blau Syndrome: NOD2-related systemic autoinflammatory granulomatosis.
Takada S; Saito MK; Kambe N
G Ital Dermatol Venereol; 2020 Oct; 155(5):537-541. PubMed ID: 32618442
[TBL] [Abstract][Full Text] [Related]
3. Nucleotide-binding oligomerization domain containing 2: structure, function, and diseases.
Yao Q
Semin Arthritis Rheum; 2013 Aug; 43(1):125-30. PubMed ID: 23352252
[TBL] [Abstract][Full Text] [Related]
4. Pluripotent stem cell models of Blau syndrome reveal an IFN-γ-dependent inflammatory response in macrophages.
Takada S; Kambe N; Kawasaki Y; Niwa A; Honda-Ozaki F; Kobayashi K; Osawa M; Nagahashi A; Semi K; Hotta A; Asaka I; Yamada Y; Nishikomori R; Heike T; Matsue H; Nakahata T; Saito MK
J Allergy Clin Immunol; 2018 Jan; 141(1):339-349.e11. PubMed ID: 28587749
[TBL] [Abstract][Full Text] [Related]
5. Blau syndrome NOD2 mutations result in loss of NOD2 cross-regulatory function.
Mao L; Dhar A; Meng G; Fuss I; Montgomery-Recht K; Yang Z; Xu Q; Kitani A; Strober W
Front Immunol; 2022; 13():988862. PubMed ID: 36189261
[TBL] [Abstract][Full Text] [Related]
6. A novel mutation in early-onset sarcoidosis/Blau syndrome: an association with Propionibacterium acnes.
Okazaki F; Wakiguchi H; Korenaga Y; Nakamura T; Yasudo H; Uchi S; Yanai R; Asano N; Hoshii Y; Tanabe T; Izawa K; Honda Y; Nishikomori R; Uchida K; Eishi Y; Ohga S; Hasegawa S
Pediatr Rheumatol Online J; 2021 Feb; 19(1):18. PubMed ID: 33602264
[TBL] [Abstract][Full Text] [Related]
7. Blau syndrome-associated Nod2 mutation alters expression of full-length NOD2 and limits responses to muramyl dipeptide in knock-in mice.
Dugan J; Griffiths E; Snow P; Rosenzweig H; Lee E; Brown B; Carr DW; Rose C; Rosenbaum J; Davey MP
J Immunol; 2015 Jan; 194(1):349-57. PubMed ID: 25429073
[TBL] [Abstract][Full Text] [Related]
8. Tofacitinib, a suppressor of NOD2 expression, is a potential treatment for Blau syndrome.
Ueki Y; Takimoto-Ito R; Saito MK; Tanizaki H; Kambe N
Front Immunol; 2023; 14():1211240. PubMed ID: 37415984
[TBL] [Abstract][Full Text] [Related]
9. Anti-TNF treatment corrects IFN-γ-dependent proinflammatory signatures in Blau syndrome patient-derived macrophages.
Kitagawa Y; Kawasaki Y; Yamasaki Y; Kambe N; Takei S; Saito MK
J Allergy Clin Immunol; 2022 Jan; 149(1):176-188.e7. PubMed ID: 34175136
[TBL] [Abstract][Full Text] [Related]
10. Role of the NOD2 genotype in the clinical phenotype of Blau syndrome and early-onset sarcoidosis.
Okafuji I; Nishikomori R; Kanazawa N; Kambe N; Fujisawa A; Yamazaki S; Saito M; Yoshioka T; Kawai T; Sakai H; Tanizaki H; Heike T; Miyachi Y; Nakahata T
Arthritis Rheum; 2009 Jan; 60(1):242-50. PubMed ID: 19116920
[TBL] [Abstract][Full Text] [Related]
11. A novel nucleotide oligomerisation domain 2 mutation in a family with Blau syndrome: Phenotype and function.
Ong LT; Nachbur U; Rowczenio D; Ziegler JB; Fischer E; Lin MW
Innate Immun; 2017 Oct; 23(7):578-583. PubMed ID: 28836875
[TBL] [Abstract][Full Text] [Related]
12. Blau syndrome with a rare mutation in exon 9 of
Velickovic J; Silan F; Bir FD; Silan C; Albuz B; Ozdemir O
Autoimmunity; 2019; 52(7-8):256-263. PubMed ID: 31556326
[TBL] [Abstract][Full Text] [Related]
13. [The present and the prospect of study on Blau syndrome/early-onset sarcoidosis].
Nakano M; Kambe N
Nihon Rinsho; 2013 Apr; 71(4):737-41. PubMed ID: 23678609
[TBL] [Abstract][Full Text] [Related]
14. Nod2-Nodosome in a Cell-Free System: Implications in Pathogenesis and Drug Discovery for Blau Syndrome and Early-Onset Sarcoidosis.
Iwasaki T; Kaneko N; Ito Y; Takeda H; Sawasaki T; Heike T; Migita K; Agematsu K; Kawakami A; Morikawa S; Mokuda S; Kurata M; Masumoto J
ScientificWorldJournal; 2016; 2016():2597376. PubMed ID: 27403452
[TBL] [Abstract][Full Text] [Related]
15. Computational model to analyze and characterize the functional mutations of NOD2 protein causing inflammatory disorder - Blau syndrome.
Thirumal Kumar D; Udhaya Kumar S; Nishaat Laeeque AS; Apurva Abhay S; Bithia R; Magesh R; Kumar M; Zayed H; George Priya Doss C
Adv Protein Chem Struct Biol; 2020; 120():379-408. PubMed ID: 32085886
[TBL] [Abstract][Full Text] [Related]
16. Clinical characteristics and treatment of 50 cases of Blau syndrome in Japan confirmed by genetic analysis of the
Matsuda T; Kambe N; Ueki Y; Kanazawa N; Izawa K; Honda Y; Kawakami A; Takei S; Tonomura K; Inoue M; Kobayashi H; Okafuji I; Sakurai Y; Kato N; Maruyama Y; Inoue Y; Otsubo Y; Makino T; Okada S; Kobayashi I; Yashiro M; Ito S; Fujii H; Kondo Y; Okamoto N; Ito S; Iwata N; Kaneko U; Doi M; Hosokawa J; Ohara O; Saito MK; Nishikomori R; ;
Ann Rheum Dis; 2020 Nov; 79(11):1492-1499. PubMed ID: 32647028
[TBL] [Abstract][Full Text] [Related]
17. Blau syndrome, the prototypic auto-inflammatory granulomatous disease.
Wouters CH; Maes A; Foley KP; Bertin J; Rose CD
Pediatr Rheumatol Online J; 2014; 12():33. PubMed ID: 25136265
[TBL] [Abstract][Full Text] [Related]
18. A case of infantile Takayasu arteritis with a p.D382E NOD2 mutation: an unusual phenotype of Blau syndrome/early-onset sarcoidosis?
Inoue Y; Kawaguchi Y; Shimojo N; Yamaguchi K; Morita Y; Nakano T; Arima T; Tomiita M; Kohno Y
Mod Rheumatol; 2013 Jul; 23(4):837-9. PubMed ID: 22821420
[TBL] [Abstract][Full Text] [Related]
19. Ocular manifestations of Blau syndrome.
Suresh S; Tsui E
Curr Opin Ophthalmol; 2020 Nov; 31(6):532-537. PubMed ID: 33009086
[TBL] [Abstract][Full Text] [Related]
20. First report of liver transplantation in Blau syndrome: The challenges faced in this rare granulomatous liver disease.
Sinharay R; McKeown L; Phillips C; Li A; Duckworth A; Hall F; Griffiths WJH
Transpl Immunol; 2021 Apr; 65():101378. PubMed ID: 33621644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
